Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy ; volume:43 ; number:1 ; day:2 ; month:9 ; year:2024 ; pages:1-14 ; date:12.2024
Journal of experimental & clinical cancer research ; 43, Heft 1 (2.9.2024), 1-14, 12.2024

Creator: He, Kewen
Puebla-Osorio, Nahum
Barsoumian, Hampartsoum B.
Sezen, Duygu
Rafiq, Zahid
Riad, Thomas S.
Hu, Yun
Huang, Ailing
Voss, Tiffany A.
Leyton, Claudia S. Kettlun
Schuda, Lily Jae
Hsu, Ethan
Heiber, Joshua
Cortez, Maria-Angelica
Welsh, James W.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13046-024-03165-x

URN: urn:nbn:de:101:1-2411252109419.823945314903

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

He, Kewen
Puebla-Osorio, Nahum
Barsoumian, Hampartsoum B.
Sezen, Duygu
Rafiq, Zahid
Riad, Thomas S.
Hu, Yun
Huang, Ailing
Voss, Tiffany A.
Leyton, Claudia S. Kettlun
Schuda, Lily Jae
Hsu, Ethan
Heiber, Joshua
Cortez, Maria-Angelica
Welsh, James W.
SpringerLink (Online service)

Other Objects (12)

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Boosting antitumor drug efficacy with chemically engineered multidomain proteins

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Regulatory T cells in immune checkpoint blockade antitumor therapy

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy

Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector

Related objects

Reset password